AZ Monthly Puff: DEA Registration Deadline, Ad Rules Live, Aspergillus Recall Hits

AZ Monthly Puff: DEA Registration Deadline, Ad Rules Live, Aspergillus Recall Hits

July 2026 arrives with compounding regulatory pressure on the desert market. The DEA registration portal for medical marijuana licensees under the Schedule III rescheduling order closed June 22, HB 2179 advertising restrictions went live July 1, and a Scottsdale lab misreport just triggered a recall of infused flower. Three moving pieces, three different pressure points on the state’s medical program.

Top Headlines This Month

• DEA opens Schedule III registration portal for medical licensees
• HB 2179 advertising restrictions take effect July 1
• Level One Labs Aspergillus misreport triggers Moonrock recall

FEDERAL: DEA REQUIRES MEDICAL MARIJUANA LICENSEE REGISTRATION UNDER SCHEDULE III ORDER

Following the April 23, 2026 rescheduling order that moved marijuana to Schedule III, the DEA opened an online registration portal on April 29, 2026, requiring all state-licensed medical marijuana cultivators, producers, distributors, transporters, and sellers to register by June 22, 2026. The registration carries an annual fee of $794 and requires applicants to disclose business and personal contact information, state license numbers, supplier names and DEA registration numbers, security measures for each location, and ownership and management histories, including any past involvement in the legacy market with no stated time limit. The portal accepted PayPal as the only digital payment method, and the DEA expects to review submitted applications before the end of 2026. Registering provides a safe harbor that allows licensees to continue state-licensed operations while the DEA processes their applications, but missing the June 22 deadline may expose licensees to federal enforcement actions. The requirement also introduces new disclosure risks: supplier relationships and ownership histories submitted through the portal may become accessible to the public through FOIA requests, and the framework signals a shift toward the kind of federal oversight structure typically applied to Schedule III controlled substances, including potential FDA oversight and prescription-based distribution requirements down the line.

Source:
https://www.fennemorelaw.com/dea-calls-for-registration-of-medical-marijuana-licensees-portal-is-open-through-june-22-2026/

ARIZONA: HB 2179 MARIJUANA ADVERTISING RESTRICTIONS IN EFFECT AS OF JULY 1

Arizona HB 2179, sponsored by Representative Bliss of Legislative District 1, took effect July 1, 2026, establishing a comprehensive set of advertising restrictions for marijuana establishments and nonprofit medical marijuana dispensaries. The law prohibits advertising directed at individuals under 21, the use of child-appealing imagery, advertising featuring consumption images or potency and THC levels, and placement of billboard ads within 1,000 radial feet of child care centers, churches, substance abuse recovery facilities, public parks or playgrounds, and public or private schools serving preschool through grade 12. Electronic advertising through social media or websites and sporting event sponsorships are only permitted if at least 73.6% of the expected audience is 21 or older, or the sponsored organization provides written approval. All marijuana advertising must carry the warning: Do not use marijuana if you are under 21 years of age or pregnant. Keep marijuana out of reach of children. Printed warnings must occupy at least 10% of the advertisement area in black font on a white background, and billboard warnings must be at least 10% of the largest type used. The Arizona Attorney General enforces the restrictions, and according to HB 2179, marijuana establishments have 14 days to come into compliance after being notified of a violation. Non-marijuana entities that advertise marijuana products face civil penalties of $20,000 per violation, with funds directed to the Smart and Safe Arizona Fund. Advertising platforms may only host marijuana ads when authorized by a licensed establishment or dispensary that is identified by name and license number in the ad.

Source:
https://www.azleg.gov/legtext/57leg/1R/summary/H.HB2179_021125_SENATEENGROSSED.DOCX.htm

ARIZONA: LEVEL ONE LABS ASPERGILLUS MISREPORT TRIGGERS DR. ZODIAK’S MOONROCK RECALL

The Arizona Department of Health Services announced a voluntary recall of Angel City infused flower, specifically Dr. Zodiak’s Moonrock Infused Bulk Snowballz batch AC120225, after state inspectors found that Scottsdale-based Level One Labs had reported failed Aspergillus test results to marijuana establishments as passing. Aspergillus is a fungus that can cause allergic reactions or infection, primarily affecting people with weakened immune systems or underlying lung conditions, with symptoms including cold-like symptoms, coughing, wheezing, shortness of breath, and chest pain. ADHS contacted dispensaries carrying the product, pulled possibly contaminated flower from shelves, and quarantined it at the point of sale pending secondary confirmatory testing. Web searches suggest the brand’s products have, at least at some point, been sold at several Valley dispensaries, including Cookies in Tempe and locations of The Mint and Nirvana. As of the announcement, no illnesses have been reported. The incident points to a gap in Arizona’s lab oversight framework, where a failed fungal contamination result moved through a testing lab and onto dispensary shelves before state inspectors intervened. Notably, ADHS did not disclose the license holder growing the Dr. Zodiak’s Moonrock product, a departure from the department’s standard practice in past recall notices.

Source:
https://www.phoenixnewtimes.com/news/weed-scottsdale-lab-recalled-possible-fungus-issue-40679035/

The Bottom Line

Between the federal DEA registration rollout under Schedule III, HB 2179’s advertising overhaul, and a lab oversight failure surfacing in Scottsdale, this period stacked federal, state, and compliance pressure on the same medical program at once. Each development touches a different part of the supply chain, from ownership disclosures to billboard placement to fungal testing.